Announcement on the Company's Board resolution
to increase the investment on TOT Biopharm International
Company Limited
Date of events
2022/05/31
To which item it meets
paragraph 20
Statement
1.Name of the securities:
Common shares of TOT Biopharm International Company Limited.
2.Trading date:2022/05/31
3.Amount, unit price, and total monetary amount of the
transaction:
The total amount does not exceed HKD110 million.
4.Gain (or loss) through disposal (not applicable in
case of acquisition of securities):NA
5.Relationship with the underlying company of the trade:
TOT Biopharm International Company Limited is one of the portfolio
companies under the Company's investment, in which the Company holds
29.19% of the shares.
6.Current cumulative amount held, monetary value, and
shareholding percentage of cumulative holdings of the
securities being traded (including the current trade),
and status of any restriction of rights (e.g., pledges):
Cumulative amount held:
Maximum monetary value:NTD2,435,144thousand
(restricted market value NTD1,332,000 thousand)
7.Current ratio of securities investment (including the
current trade) to the total assets and equity attributable
to owners of parent as shown in the most recent financial
statement and working capital as shown in the most recent
financial statement as of the present, as listed in the
Regulations Governing the Acquisition and Disposal of
Assets by Public Companies: Ratio to total assets:
Proportion accounted to the total assets：77.62%
Proportion of equity attributable to Stockholders of the Company：98.83%
Operating capital：NTD2,613,396 thousand
8.Concrete purpose of the acquisition or disposal:
Long term investment
9.Whether the directors expressed any objection to
the current transaction:No
10.Whether the counterparty of the current transaction
is a related party:Yes
11.Trading counterparty and its relationship to the
Company:
TOT Biopharm International Company Limited is one of the portfolio
companies under the Company's investment, in which the Company holds
29.19% of the shares.
12.Date of the board of directors' resolution:2022/05/31
13.Date of ratification by supervisors or approval by
the audit committee:2022/05/31
14.Any other matters that need to be specified:
The Company intends to participate in the capital increase with new
shares issued by TOT Biopharm International Company Limited for no more
than HKD$110 million. Nevertheless, the plan for capital increase shall
only proceed after the resolution of the Extraordinary General Meeting
of TOT Biopharm is passed.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Center Laboratories Inc. published this content on 31 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 May 2022 09:39:11 UTC.
Center Laboratories, Inc. is a Taiwan-based company principally engaged in the production, marketing and distribution of infant nutrition products, as well as the research and development, processing, production, packaging, marketing and sales of dairy products. The Company's main products include dairy products and probiotic products. The Company is also involved in the manufacture, wholesale and retail of western medicines. The Company distributes its products in the domestic market and to overseas markets.
CENTER LABORATORIES, INC. 
